Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer’s disease at the Society for Neuroscience’s Neuroscience 2023 meeting, to be held on November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C.
In this model, tauopathy was induced in older non-human primates (NHPs) through double-tau mutations introduced in entorhinal cortex bilaterally. NHPs were administered SLS-005 weekly and demonstrated a 46% reduction in tau protein and an 18% reduction in NfL neurofilament light chain (NfL) protein biomarker from baseline values over 6 months in a preliminary analysis. NfL is a non-specific biomarker for several neurodegenerative conditions, including Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). Previously, SLS-005 demonstrated an efficacious reduction of mHTT, the mutant protein implicated in Huntington’s disease (HD), by 77% in striatum and 84% in cortex, along with a 100% reduction of Darpp-32, which is associated with neuronal dysfunction in striatum of the R6/2 severe HD model.
“The current results further validate SLS-005 as a potential pipeline-in-a-product by activating autophagy, a novel mechanism of action that would clear only mutant, toxic, and aggregating proteins. This has now been demonstrated in two aggressive and fast progressing neurodegenerative disease models of Huntington’s disease and Alzheimer’s disease across two species, mice and non-human primates, respectively,” said Krishna Subramanian, Ph.D., Vice President, Non-Clinical Development and Translational Science at Seelos.
